"{\n \"business_address\": \"ONE BAXTER PKWY, DF2-1W, DEERFIELD, IL 60015\", \n \"business_phone_no\": \"8479482000\", \n \"ceo\": \"Joe Almeida\", \n \"cik\": \"0000010456\", \n \"company_url\": \"www.baxter.com\", \n \"employees\": 48000, \n \"entity_legal_form\": \"OTHER\", \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"Illinois\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Health Services\", \n \"industry_group\": \"Medical Instruments & Supplies\", \n \"latest_filing_date\": \"2017-08-07\", \n \"legal_name\": \"BAXTER INTERNATIONAL INC\", \n \"lei\": \"J5OIVXX3P24RJRW5CK77\", \n \"long_description\": \"Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. It offers its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. The company has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. It also has a strategic partnership with ScinoPharm Taiwan, Ltd. to develop, manufacture, and commercialize five injectable drugs for cancer treatments, such as lung cancer, multiple myeloma, and breast cancer, as well as medication to treat nausea and vomiting, and side effects of chemotherapy. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.\", \n \"mailing_address\": \"ONE BAXTER PARKWAY, DF2-1W, DEERFIELD, IL 60015\", \n \"name\": \"Baxter International Inc\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000BCVJ77\", \n   \"composite_figi_ticker\": \"BAX:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000BCVJ77\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"BAX:US\", \n   \"figi_uniqueid\": \"EQ0010017700001000\", \n   \"last_crsp_adj_date\": \"2017-08-30\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"BAXTER INTERNATIONAL INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"BAX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000FNT572\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"BTL:GB\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-08-30\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000C4CCW2\", \n   \"composite_figi_ticker\": \"BAX:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006M6YFB5\", \n   \"figi_exch_cntry\": \"BW\", \n   \"figi_ticker\": \"BAX:BW\", \n   \"figi_uniqueid\": \"EQ0010017700022000\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"US0718131099\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAM\", \n   \"figi\": \"BBG000FNT778\", \n   \"figi_exch_cntry\": \"GH\", \n   \"figi_ticker\": \"BTL:GH\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-08-30\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAM\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"HAM\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000FNT536\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"BTL:GM\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-05-31\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000FNT3T3\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"BTL:GS\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-05-31\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000FNT2T5\", \n   \"figi_exch_cntry\": \"GY\", \n   \"figi_ticker\": \"BTL:GY\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-08-30\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG0058MHBF2\", \n   \"composite_figi_ticker\": \"BAXCHF:XL\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XLON\", \n   \"figi\": \"BBG0058MHBQ0\", \n   \"figi_exch_cntry\": \"XL\", \n   \"figi_ticker\": \"BAXCHF:XL\", \n   \"figi_uniqueid\": \"EQ0000000031670796\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XLON\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"LSE\", \n   \"ticker\": \"0QK8\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000FNT242\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"BTL:GD\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-05-31\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"BTL\"\n  }, \n  {\n   \"composite_figi\": \"BBG001QYJLW2\", \n   \"composite_figi_ticker\": \"BAX*:MM\", \n   \"currency\": \"MXN\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMEX\", \n   \"figi\": \"BBG001QYJLX1\", \n   \"figi_exch_cntry\": \"MM\", \n   \"figi_ticker\": \"BAX*:MM\", \n   \"figi_uniqueid\": \"EQ0000000017691574\", \n   \"last_crsp_adj_date\": \"2017-05-10\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMEX\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"MEX\", \n   \"ticker\": \"BAX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000C4CCW2\", \n   \"composite_figi_ticker\": \"BAX:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG000C4CF46\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"BAX:SE\", \n   \"figi_uniqueid\": \"EQ0010017700022000\", \n   \"last_crsp_adj_date\": \"2017-06-27\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"BAX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000FNRZG8\", \n   \"composite_figi_ticker\": \"BTL:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000FNT1S8\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"BTL:GF\", \n   \"figi_uniqueid\": \"EQ0010017700001003\", \n   \"last_crsp_adj_date\": \"2017-08-30\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"BAXTER INTERNATIONAL INC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P1K3\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"BTL\"\n  }\n ], \n \"short_description\": \"Baxter International, Inc. provides a broad portfolio of essential renal and hospital products, including acute and chronic dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems; and pharmacy automation, software and services. The company products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctor's offices and by patients at home under physician supervision. It operates through the following segments: Hospital Products and Renal. The Hospital Products segment intravenous IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation. The Renal segment provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis, home HD, continuous renal replacement therapy and additional dialysis services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.\", \n \"sic\": 3841, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"BAX\"\n}"